SNDX-5613-0708: A Phase 1, Open-Label, Dose-escalation, and Dose-Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin1 (NPM1), and Nucleoporin 98 (NUP98) Genes

A Phase 1, Open-Label, Dose-escalation, and Dose-Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin1 (NPM1), and Nucleoporin 98 (NUP98) Genes
Principal Investigator
Emadi, Ashkan
Phase
I
Age Group
Adult
Applicable Disease Sites
Leukemia
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Abby Swiger, RN
Research Nurse
Phone: +1 304-293-1683
Email:

View on ClinicalTrials.gov

Quick Search

Use the full search for additional searching options.